Literature-related discovery (LRD): Potential treatments for Multiple Sclerosis

[1]  Ronald N. Kostoff,et al.  Literature-related discovery , 2009, Annu. Rev. Inf. Sci. Technol..

[2]  Ronald N. Kostoff,et al.  Literature-Related Discovery (LRD): Introduction and background , 2008 .

[3]  Ronald N. Kostoff,et al.  Literature-related discovery (LRD): Methodology , 2008 .

[4]  Ronald N. Kostoff,et al.  Literature-Related Discovery (LRD): Potential treatments for Parkinson's Disease , 2008 .

[5]  Ronald N. Kostoff,et al.  Literature-related discovery (LRD): Potential treatments for Raynaud's Phenomenon☆ , 2008 .

[6]  Ronald N. Kostoff,et al.  Literature-related discovery (LRD): Potential treatments for cataracts , 2008 .

[7]  P. Shanthi,et al.  Restorative and synergistic efficacy of Kalpaamruthaa, a modified Siddha preparation, on an altered antioxidant status in adjuvant induced arthritic rat model. , 2007, Chemico-biological interactions.

[8]  R. Ransohoff,et al.  Natalizumab for multiple sclerosis. , 2007, The New England journal of medicine.

[9]  Bernhard Hemmer,et al.  Treatment and treatment trials in multiple sclerosis , 2007, Current opinion in neurology.

[10]  Jin Won Hyun,et al.  Rhapontigenin from Rheum undulatum Protects Against Oxidative-Stress-Induced Cell Damage Through Antioxidant Activity , 2007, Journal of toxicology and environmental health. Part A.

[11]  Gavin Giovannoni,et al.  Multiple sclerosis: the environment and causation , 2007, Current opinion in neurology.

[12]  Sarah Morrow,et al.  The safety and efficacy of IFN-β products for the treatment of multiple sclerosis , 2007 .

[13]  T. Holmøy,et al.  Immunopathogenesis of multiple sclerosis: concepts and controversies , 2007, Acta neurologica Scandinavica. Supplementum.

[14]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[15]  Masahiro Akishita,et al.  Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. , 2007, Atherosclerosis.

[16]  Moses Rodriguez,et al.  Effectors of Demyelination and Remyelination in the CNS: Implications for Multiple Sclerosis , 2007, Brain pathology.

[17]  Manish S Lavhale,et al.  Evaluation of free radical scavenging activity of Butea monosperma Lam. , 2007, Indian journal of experimental biology.

[18]  A. Mackay-Sim,et al.  Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  G Giorgi,et al.  Protective effect of silymarin on oxidative stress in rat brain. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[20]  J. Correale,et al.  The blood–brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting , 2007, Autoimmunity.

[21]  Vivek Misra,et al.  Evolving therapies for multiple sclerosis. , 2007, International review of neurobiology.

[22]  S. Morrow,et al.  The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. , 2007, Expert opinion on drug safety.

[23]  J. Ríos,et al.  Tiliroside and gnaphaliin inhibit human low density lipoprotein oxidation. , 2007, Fitoterapia.

[24]  Ming Zhan,et al.  Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress , 2007, NeuroMolecular Medicine.

[25]  Declan P Naughton,et al.  Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases. , 2006, Behavioural pharmacology.

[26]  C. Devi,et al.  Gastroprotective action of Cissus quadrangularis extract against NSAID induced gastric ulcer: role of proinflammatory cytokines and oxidative damage. , 2006, Chemico-biological interactions.

[27]  H. Rossman,et al.  Managing the symptoms of multiple sclerosis: a multimodal approach. , 2006, Clinical therapeutics.

[28]  Sang-Hyun Kim,et al.  Artemisia iwayomogi Inhibits Immediate-Type Allergic Reaction and Inflammatory Cytokine Secretion , 2006, Immunopharmacology and immunotoxicology.

[29]  D. Laub,et al.  The effect on health of alternate day calorie restriction: eating less and more than needed on alternate days prolongs life. , 2006, Medical hypotheses.

[30]  M Filippi,et al.  Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. , 2006, Archives of neurology.

[31]  Hye-Young Shin,et al.  Sopoongsan Inhibits Mast Cell-Mediated Anaphylactic Reactions and Inflammatory Cytokine Secretion , 2005, International Archives of Allergy and Immunology.

[32]  L. Kellaway,et al.  Herbal Complement Inhibitors in the Treatment of Neuroinflammation: Future Strategy for Neuroprotection , 2005, Annals of the New York Academy of Sciences.

[33]  D. Sok,et al.  Protection by petaslignolide A, a major neuroprotective compound in the butanol extract of Petasites japonicus leaves, against oxidative damage in the brains of mice challenged with kainic acid. , 2005, Journal of agricultural and food chemistry.

[34]  Yingjin Yuan,et al.  Aqueous extract of Salvia miltiorrhiza attenuates increased endothelial permeability induced by tumor necrosis factor-alpha. , 2005, International immunopharmacology.

[35]  Ş. Şahin,et al.  The effect of Nigella sativa oil against experimental allergic encephalomyelitis via nitric oxide and other oxidative stress parameters. , 2005, Cellular and molecular biology.

[36]  P. Kloetzel,et al.  Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.

[37]  J. Bright,et al.  Quercetin, a Flavonoid Phytoestrogen, Ameliorates Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through JAK-STAT Pathway in T Lymphocyte , 2004, Journal of Clinical Immunology.

[38]  William H Stuart,et al.  Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. , 2004, Journal of managed care pharmacy : JMCP.

[39]  I. A. Ross,et al.  Mangifera indica L. , 2003 .

[40]  Rhonda R. Voskuhl,et al.  Gender issues and multiple sclerosis , 2002, Current neurology and neuroscience reports.

[41]  George Karypis,et al.  CLUTO - A Clustering Toolkit , 2002 .

[42]  E. Candelario-Jalil,et al.  Mangifera indica L. extract (QF808) reduces ischaemia-induced neuronal loss and oxidative damage in the gerbil brain , 2001, Free radical research.

[43]  R. Kostoff.  Energy restriction. , 2001, The American journal of clinical nutrition.

[44]  T. Nobori,et al.  Effects of the Japanese herbal medicine 'Inchinko-to' (TJ-135) on concanavalin A-induced hepatitis in mice. , 2000, Clinical science.

[45]  M. Memariani,et al.  Quercetin , 2011, Nutraceuticals.

[46]  B. Weinshenker,et al.  The epidemiology of multiple sclerosis. , 1997, Mayo Clinic proceedings.

[47]  G.L. Boccaccio,et al.  Multiple sclerosis: From a myelin point of view , 1996, Journal of neuroscience research.

[48]  Ruston M. Hunt,et al.  Search technology, Inc. , 1989, CHI '89.